Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma

Urinary Bladder Squamous Cell Carcinoma Clinical Trial

Official title:

Outcome of Radical Radiation Therapy in Squampus Cell Carcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04815629
• Other study ID #: Radiotherapy in bladder cancer
• Status: Not yet recruiting
• Start date: April 1, 2022
• Est. completion date: April 1, 2023

Study information

• Verified date: August 2021
• Source: Assiut University
• Contact: Aya Anter Ali, master degree
• Phone: +201120516228
• Email: antaraya333[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Detection of distribution of clinico-pathological features of squamous cell carcinoma of urinary bladder and their relation to treatment outcome.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: April 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. age 18-70 .

2. histologically proved urinary bladder squamous cell carcinoma.

3. non-metastatic disease.

4. all patients who underwent radical treatment or bladder preserving approach.

5. patient with isolated urinary bladder carcinoma (no other or previous primary).

Exclusion Criteria:

1. age < 18 , > 70.

2. patient not documented having bladder squamous cell carcinoma by biopsy (cystoscopic or operative).

3. metastatic disease.

4. patient with synchronous or metachronous double primary

Related Conditions & MeSH terms

• Carcinoma
• Urinary Bladder Squamous Cell Carcinoma

Intervention

Radiation:
• Radiotherapy
Radiotion therapy squamous cell carcinoma in cancer bladder

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (1)

1. Messing EM. Urothelial tumours of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, Partn AW, Peters CA (editors). Campbell-Walsh Urology. 9th(3). Philadelphia: Saunders Elsevier 2007: pp.2407-2446. 2. Christopher Ho Chee Kong, Praveen Singam, Goh Eng Hong, Lee Boon Cheok, Muhammad Azrif, Azmi Mohd Tamil et.al (2010). Clinicopathological features of bladder tumours in a single insttuton in Malaysia. Asian Pasifc J cancer Prev. 2010; 11: 149-152. 3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statstcs. CA Cancer J Clin. 2009 ; 59: 529-533. 4.Zarzour AH , Selim M, Abd -Elsayed A et al., muscle invasive bladder cancer in uppr Egypt : the shift in risk factors and tumor characteristics, license Bio Med central BMC Cancer doi.:10.1186 / 1471-2407-8-250-,2008. 5.Amal S. Ibrahim, Nabiel N Mikhail et al . Egypt National Cancer Registry Damietta profile - 2009: publication number RR2 July, 2011. 6.M.Nabil El- Bolkiny , M.Akram Nouh , Tarek N.El-Bolkiny et al.topographic pathology of cancer , the national cancer institute, Cairo University , 2008. 7.Jason A.Efstathiou, Anthony L.Zietman, Jhon J. Coen, clinical Radiation Oncology , bladder cancer ;3rd edition : p1216-1241, 2012.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease free survival	Disease free survival	baseline